Article Text

other Versions

Original article
Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma
  1. Matthew F Buas1,
  2. Qianchuan He1,
  3. Lisa G Johnson1,
  4. Lynn Onstad1,
  5. David M Levine2,
  6. Aaron P Thrift3,
  7. Puya Gharahkhani4,
  8. Claire Palles5,
  9. Jesper Lagergren6,7,
  10. Rebecca C Fitzgerald8,
  11. Weimin Ye9,
  12. Carlos Caldas10,
  13. Nigel C Bird11,
  14. Nicholas J Shaheen12,
  15. Leslie Bernstein13,
  16. Marilie D Gammon14,
  17. Anna H Wu15,
  18. Laura J Hardie16,
  19. Paul D Pharoah17,18,
  20. Geoffrey Liu19,
  21. Prassad Iyer20,
  22. Douglas A Corley21,22,
  23. Harvey A Risch23,
  24. Wong-Ho Chow24,
  25. Hans Prenen25,
  26. Laura Chegwidden26,
  27. Sharon Love27,
  28. Stephen Attwood28,
  29. Paul Moayyedi29,
  30. David MacDonald30,
  31. Rebecca Harrison31,
  32. Peter Watson32,
  33. Hugh Barr33,
  34. John deCaestecker34,
  35. Ian Tomlinson5,
  36. Janusz Jankowski35,
  37. David C Whiteman36,
  38. Stuart MacGregor4,
  39. Thomas L Vaughan1,37,
  40. Margaret M Madeleine1,37
  1. 1Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
  2. 2Department of Biostatistics, University of Washington, School of Public Health, Seattle, Washington, USA
  3. 3Department of Medicine, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas, USA
  4. 4Queensland Institute of Medical Research Berghofer Medical Research Institute Brisbane, Queensland, Australia
  5. 5Wellcome Trust Centre for Human Genetics and NIHR Comprehensive Biomedical Research Centre, University of Oxford, Oxford, UK
  6. 6Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
  7. 7Division of Cancer Studies, King's College London, UK
  8. 8Medical Research Council (MRC) MRC Cancer Unit, Hutchison-MRC Research Centre, University of Cambridge, Cambridge, UK
  9. 9Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
  10. 10Cancer Research UK, Cambridge Institute, Cambridge, UK
  11. 11Department of Oncology, Medical School, University of Sheffield, Sheffield, UK
  12. 12Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA
  13. 13Department of Population Sciences, Beckman Research Institute and City of Hope Comprehensive Cancer Center, Duarte, California, USA
  14. 14Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, USA
  15. 15Department of Preventive Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California, USA
  16. 16Division of Epidemiology, University of Leeds, Leeds, UK
  17. 17Department of Oncology, University of Cambridge, Cambridge, UK
  18. 18Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
  19. 19Pharmacogenomic Epidemiology, Ontario Cancer Institute, Toronto, Ontario, Canada
  20. 20Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
  21. 21Division of Research, Kaiser Permanente Northern California, Oakland, California, USA
  22. 22San Francisco Medical Center, Kaiser Permanente Northern California, San Francisco, California, USA
  23. 23Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut, USA
  24. 24Department of Epidemiology, MD Anderson Cancer Center, Houston, Texas, USA
  25. 25Department of Digestive Oncology, University Hospital Gasthuisberg, Leuven, Belgium
  26. 26University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK
  27. 27Centre for Statistics in Medicine and Oxford Clinical Trials Research Unit, Oxford, UK
  28. 28Department of General Surgery, North Tyneside General Hospital, North Shields, UK
  29. 29Department of Medicine, McMaster University, Hamilton, Ontario, Canada
  30. 30Department of Oral Biological and Medical Sciences, University of British Columbia, Vancouver, British Columbia, Canada
  31. 31Department of Pathology, Leicester Royal Infirmary, Leicester, UK
  32. 32Department of Medicine, Institute of Clinical Science, Royal Victoria Hospital, Belfast, UK
  33. 33Department of Upper GI Surgery, Gloucestershire Royal Hospital, Gloucester, UK
  34. 34Department of Gastroenterology, Leicester General Hospital, Leicester, UK
  35. 35UClan Medical School, West Lakes Campus, Rm 127 Lindow Centre, Cumbria, UK
  36. 36Cancer Control, QIMR Berghofer Medical Research Institute, Brisbane, Australia
  37. 37Department of Epidemiology, University of Washington, School of Public Health, Seattle, Washington, USA
  1. Correspondence to Professor Margaret M Madeleine, Department of Epidemiology, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, M4-C308, Seattle, WA 98109, USA; mmadelei{at}


Objective Oesophageal adenocarcinoma (OA) incidence has risen sharply in Western countries over recent decades. Local and systemic inflammation is considered an important contributor to OA pathogenesis. Established risk factors for OA and its precursor, Barrett's oesophagus (BE), include symptomatic reflux, obesity and smoking. The role of inherited genetic susceptibility remains an area of active investigation. Here, we explore whether germline variation related to inflammatory processes influences susceptibility to BE/OA.

Design We used data from a genomewide association study of 2515 OA cases, 3295 BE cases and 3207 controls. Our analysis included 7863 single-nucleotide polymorphisms (SNPs) in 449 genes assigned to five pathways: cyclooxygenase (COX), cytokine signalling, oxidative stress, human leucocyte antigen and nuclear factor-κB. A principal components-based analytic framework was employed to evaluate pathway-level and gene-level associations with disease risk.

Results We identified a significant signal for the COX pathway in relation to BE risk (p=0.0059, false discovery rate q=0.03), and in gene-level analyses found an association with microsomal glutathione-S-transferase 1 (MGST1); (p=0.0005, q=0.005). Assessment of 36 MGST1 SNPs identified 14 variants associated with elevated BE risk (q<0.05). Four of these were subsequently confirmed (p<5.5×10−5) in a meta-analysis encompassing an independent set of 1851 BE cases and 3496 controls, and are known strong expression quantitative trait loci for MGST1. Three such variants were associated with similar elevations in OA risk.

Conclusions This study provides the most comprehensive evaluation of inflammation-related germline variation in relation to risk of BE/OA and suggests that variants in MGST1 influence disease susceptibility.


Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.